AU2016252992A1 - Bromodomain inhibitor - Google Patents

Bromodomain inhibitor Download PDF

Info

Publication number
AU2016252992A1
AU2016252992A1 AU2016252992A AU2016252992A AU2016252992A1 AU 2016252992 A1 AU2016252992 A1 AU 2016252992A1 AU 2016252992 A AU2016252992 A AU 2016252992A AU 2016252992 A AU2016252992 A AU 2016252992A AU 2016252992 A1 AU2016252992 A1 AU 2016252992A1
Authority
AU
Australia
Prior art keywords
pharmaceutical composition
methylsulfonylphenyl
methylisoquinolin
cyclopropylmethoxy
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2016252992A
Other languages
English (en)
Inventor
Juan Manuel Betancort
Jeffrey Alan Stafford
Ryan STANSFIELD
James Marvin Veal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Quanticel Research Inc
Original Assignee
Celgene Quanticel Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Quanticel Research Inc filed Critical Celgene Quanticel Research Inc
Publication of AU2016252992A1 publication Critical patent/AU2016252992A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2016252992A 2015-04-22 2016-04-22 Bromodomain inhibitor Abandoned AU2016252992A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562151205P 2015-04-22 2015-04-22
US62/151,205 2015-04-22
PCT/US2016/029029 WO2016172618A1 (en) 2015-04-22 2016-04-22 Bromodomain inhibitor

Publications (1)

Publication Number Publication Date
AU2016252992A1 true AU2016252992A1 (en) 2017-11-09

Family

ID=57143581

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016252992A Abandoned AU2016252992A1 (en) 2015-04-22 2016-04-22 Bromodomain inhibitor

Country Status (22)

Country Link
US (1) US20160310423A1 (enExample)
EP (1) EP3285770A4 (enExample)
JP (1) JP2018513863A (enExample)
KR (1) KR20170139119A (enExample)
CN (1) CN107613981A (enExample)
AR (1) AR104340A1 (enExample)
AU (1) AU2016252992A1 (enExample)
BR (1) BR112017022691A2 (enExample)
CA (1) CA2983446C (enExample)
CL (1) CL2017002679A1 (enExample)
CO (1) CO2017011482A2 (enExample)
EA (1) EA201792317A1 (enExample)
EC (1) ECSP17071545A (enExample)
HK (1) HK1243948A1 (enExample)
IL (1) IL255120B (enExample)
MX (2) MX377159B (enExample)
PE (1) PE20180036A1 (enExample)
PH (1) PH12017501933A1 (enExample)
SG (1) SG11201708627TA (enExample)
TW (1) TW201642860A (enExample)
WO (1) WO2016172618A1 (enExample)
ZA (1) ZA201707186B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR104259A1 (es) 2015-04-15 2017-07-05 Celgene Quanticel Res Inc Inhibidores de bromodominio
US10702517B2 (en) 2015-04-22 2020-07-07 Celgene Quanticel Research, Inc. Bromodomain inhibitor
GB201506872D0 (en) 2015-04-22 2015-06-03 Ge Oil & Gas Uk Ltd Novel compounds
US10150754B2 (en) 2016-04-19 2018-12-11 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
EP3528810A4 (en) * 2016-10-20 2020-06-17 Celgene Quanticel Research, Inc. BROMDOMAIN INHIBITOR
WO2018081475A1 (en) 2016-10-27 2018-05-03 Celgene Quanticel Research, Inc. Bromodomain and extra-terminal protein inhibitor combination therapy
SG11202100346PA (en) * 2018-07-23 2021-02-25 Celgene Quanticel Research Inc Process for the preparation of bromodomain inhibitor
JP2024507232A (ja) * 2021-02-22 2024-02-16 セルジーン・クオンティセル・リサーチ・インコーポレイテッド 前立腺がんの治療に用いるブロモドメイン（ｂｅｔ）阻害剤

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0420722D0 (en) * 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
GB0919434D0 (en) * 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
WO2013097052A1 (en) * 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors
LT3057586T (lt) * 2013-10-18 2020-03-10 Celgene Quanticel Research, Inc. Bromodomeno inhibitoriai
EP3528810A4 (en) * 2016-10-20 2020-06-17 Celgene Quanticel Research, Inc. BROMDOMAIN INHIBITOR

Also Published As

Publication number Publication date
CA2983446A1 (en) 2016-10-27
ZA201707186B (en) 2019-01-30
PH12017501933A1 (en) 2018-03-19
HK1243948A1 (zh) 2018-07-27
JP2018513863A (ja) 2018-05-31
MX377159B (es) 2025-03-07
KR20170139119A (ko) 2017-12-18
MX2020010899A (es) 2022-02-15
NZ736630A (en) 2024-03-22
EP3285770A4 (en) 2018-10-31
CN107613981A (zh) 2018-01-19
MX390077B (es) 2025-03-20
US20160310423A1 (en) 2016-10-27
MX2017013501A (es) 2018-02-09
CL2017002679A1 (es) 2018-05-25
TW201642860A (zh) 2016-12-16
AR104340A1 (es) 2017-07-12
PE20180036A1 (es) 2018-01-09
IL255120A0 (en) 2017-12-31
SG11201708627TA (en) 2017-11-29
BR112017022691A2 (pt) 2018-07-17
CO2017011482A2 (es) 2018-01-31
ECSP17071545A (es) 2017-12-01
CA2983446C (en) 2024-04-09
WO2016172618A1 (en) 2016-10-27
EA201792317A1 (ru) 2018-03-30
IL255120B (en) 2021-03-25
EP3285770A1 (en) 2018-02-28

Similar Documents

Publication Publication Date Title
CA2983446C (en) Bromodomain inhibitor
AU2019394974B2 (en) Crystalline forms of a compound for treating or preventing gout or hyperuricemia
JP2024056905A (ja) ブロモドメイン阻害剤
JP7528080B2 (ja) 痛風または高尿酸血症を処置または予防するための方法
CA3140412A1 (en) Compound for treating gout or hyperuricemia
US20230301983A1 (en) Bromodomain inhibitor
WO2023098872A1 (en) Crystalline forms of a compound for treating or preventing gout or hyperuricemia
EA043666B1 (ru) Кристаллические формы соединения для лечения или профилактики подагры или гиперурикемии

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application